SLC5A2 and diabetes mellitus: Sodium glucose cotransporter 2 (SGLT2) inhibitors, an effective therapeutic option for diabetes, increase the urinary excretion of glucose, which subsequently improves hyperglycemia and promotes weight loss [103].